2JQ Stock Overview
A clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gritstone bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.042 |
| 52 Week High | US$2.73 |
| 52 Week Low | US$0.04 |
| Beta | 0.63 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.47% |
| 33 Year Change | -99.60% |
| 5 Year Change | -99.44% |
| Change since IPO | -99.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2JQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | -96.5% | -18.3% | 8.6% |
Return vs Industry: 2JQ underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 2JQ underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 2JQ volatility | |
|---|---|
| 2JQ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2JQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2JQ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 231 | Andrew Allen | gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
| 2JQ fundamental statistics | |
|---|---|
| Market cap | €3.49m |
| Earnings (TTM) | -€126.98m |
| Revenue (TTM) | €13.95m |
0.3x
P/S Ratio0.0x
P/E RatioIs 2JQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2JQ income statement (TTM) | |
|---|---|
| Revenue | US$14.61m |
| Cost of Revenue | US$119.55m |
| Gross Profit | -US$104.94m |
| Other Expenses | US$28.09m |
| Earnings | -US$133.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | -718.30% |
| Net Profit Margin | -910.56% |
| Debt/Equity Ratio | 182.5% |
How did 2JQ perform over the long term?
See historical performance and comparison